Recurrent HCC: Adjuvant sorafenib after RFA offers survival benefit over RFA aloneAugust 22, 2022Hepatocellular Carcinoma
HBV-related HCC: Clinical outcomes of patients on anti-PD-1 therapy not compromised by HBV viral loadAugust 22, 2022Hepatocellular Carcinoma
Advanced HCC with PVTT: Hepatic arterial infusion more effective than transcatheter arterial chemoembolizationAugust 22, 2022Hepatocellular Carcinoma
Alcoholism and ALDH2 rs671 polymorphism in patients with HBV-related cirrhosis necessitate close monitoring for HCCAugust 22, 2022Hepatocellular Carcinoma
Liver Transplant for HCC: Long-term outcome of downstaging to within Milan criteria support national downstaging policyAugust 22, 2022Hepatocellular Carcinoma
Liver Transplant for HCC: Long-term outcome of downstaging to within Milan criteria support national downstaging policyAugust 22, 2022Hepatocellular Carcinoma
Commentary: HCC With HCV and Treatment Comparisons for Unresectable HCC, August 2022July 28, 2022Hepatocellular Carcinoma
Beta-adrenergic receptor blocker use improves overall survival in HCCJuly 27, 2022Hepatocellular Carcinoma
Lenvatinib plus IDADEB-TACE tops lenvatinib monotherapy in advanced HCCJuly 27, 2022Hepatocellular Carcinoma
Meta-analysis supports the use of direct-acting antiviral therapy in HCV-related HCCJuly 27, 2022Hepatocellular Carcinoma
Statin use ties with lower HCC risk in dialysis patients with HBV or HCV monoinfectionJuly 27, 2022Hepatocellular Carcinoma
Lenvatinib combination therapy vs monotherapy against HCC: Real-world resultsJuly 27, 2022Hepatocellular Carcinoma
Advanced HCC: Radiotherapy+anti-PD1 a better therapeutic regimen than TACE+sorafenibJuly 27, 2022Hepatocellular Carcinoma
Sustained virologic response beneficial in patients with HCV-related HCC receiving nonsurgical managementJuly 27, 2022Hepatocellular Carcinoma
